60 Degrees Pharmaceuticals Inc. (SXTP)
NASDAQ (CM) NASDAQ (CM) Primary Summary
60 Degrees Pharmaceuticals Inc. (SXTP) Upgraded to Buy: Here's What You Should Know
60 Degrees Pharmaceuticals Inc. (SXTP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
What's Going On With 60 Degrees Pharmaceuticals On Friday?
60 Degrees Pharmaceuticals Inc. (NASDAQ: SXTP) shares are down during Friday's premarket session. This follows a 9.6% decline, closing at $2.91 on Thursday.
Here's Why 60 Degrees Pharmaceuticals Inc. (SXTP) Looks Ripe for Bottom Fishing
60 Degrees Pharmaceuticals Inc. (SXTP) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
60 Degrees Pharmaceuticals Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Twin Peaks Wealth Advisors LLC TWIN PEAKS WEALTH ADVISORS, LLC | 8 | $14 | $11.44 | -$2.56 | -18.29% |
60 Degrees Pharmaceuticals Inc. Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| MK Matthew Keller HC Wainwright & Co. | -27,440.75 | $43,356.38 | $40,063.49 | $3,292.89 | 7.59% |
| LW Lucas Ward Ascendiant Capital | -2,971.28 | $5,348.3 | $4,338.07 | $1,010.23 | 18.89% |
60 Degrees Pharmaceuticals Inc. (SXTP) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has 60 Degrees Pharmaceuticals Inc. ever had a stock split?
60 Degrees Pharmaceuticals Inc. Profile
| Biotechnology Industry | Healthcare Sector | Geoffrey Stuart Dow CEO | NASDAQ (CM) Exchange | 83006G401 CUSIP |
| US Country | 3 Employees | - Last Dividend | 20 Jan 2026 Last Split | 12 Jul 2023 IPO Date |
Overview
60 Degrees Pharmaceuticals, Inc., founded in 2010 and based in Washington, D.C., specializes in the discovery, development, and commercialization of innovative therapies intended for the prevention and treatment of infectious diseases. This specialty pharmaceutical company focuses its efforts on addressing unmet medical needs within the United States. Through rigorous research and development, 60 Degrees Pharmaceuticals aims to offer groundbreaking solutions to combat various infectious diseases, thereby contributing to global health improvements.
Products and Services
- Arakoda for Malaria Preventative Treatment:
Arakoda is the flagship product of 60 Degrees Pharmaceuticals, specifically designed for the prevention of malaria. This medication stands out for its effectiveness and convenience, catering to travelers and individuals residing in malaria-prone areas. Through its innovative approach, Arakoda aims to significantly reduce the incidence of malaria infections, offering a reliable preventive solution.
- Tafenoquine (Arakoda regimen) for COVID-19:
In response to the global COVID-19 pandemic, 60 Degrees Pharmaceuticals has developed a specialized Arakoda regimen based on Tafenoquine. Currently in Phase IIb clinical trials, this treatment demonstrates the company's adaptability and commitment to addressing pressing healthcare challenges with novel therapeutic options. Tafenoquine's potential in treating COVID-19 symptoms highlights the versatility and promise of the company’s drug development endeavors.
- Tafenoquine for Babesiosis, Fungal Pneumonias, and Candidiasis Disease:
Tafenoquine, undergoing phase IIA clinical trials, showcases the broad-spectrum potential of 60 Degrees Pharmaceuticals' research, extending beyond malarial prevention. The drug's application in treating babesiosis, fungal pneumonias, and candidiasis reveals the company's pursuit of versatile antiparasitic and antifungal solutions. These trials reflect the firm's dedication to expanding its therapeutic reach to encompass a variety of infectious diseases.
- Celgosivir for Respiratory Viruses and Dengue:
Celgosivir represents another critical component of 60 Degrees Pharmaceuticals’ portfolio, targeting respiratory viruses and dengue fever. This development underscores the company's commitment to addressing viral infections that have significant impacts on public health globally. As Celgosivir progresses through the development stages, it showcases the ongoing efforts to diversify and enhance therapeutic options for viral diseases.
